Owlstone Medical Overview
Pro stress-test →Owlstone Medical, founded in 2004, is a developer of non-invasive breath-based diagnostics for cancer and infectious diseases. The Breath Biopsy platform is creating a new industry category based on routine detection and analysis of volatile organic compound (VOC) biomarkers in breath, which has the potential to revolutionize healthcare.
Strategic Profile
Pro stress-test →The company's vision is to save 100,000 lives and $1.5 billion in healthcare costs through breath-based diagnostics. In November 2025, Owlstone won an award of up to $49.1 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop at-home tests for early detection of multiple cancers. Research Products and Services are deployed at over 100 sites worldwide with major pharmaceutical companies including AstraZeneca, Actelion, and GlaxoSmithKline.
Competitive Landscape
Pro stress-test →Key competitors include Aerocrine, GattyInstruments, and Health Mirror. Owlstone faces indirect competition from traditional diagnostic modalities (endoscopy, imaging, blood tests) and emerging breath/biomarker companies. Owlstone's competitive moat lies in its proprietary VOC analysis platform, commercial-scale laboratory infrastructure, and 160+ patent portfolio.
Industry Context
Owlstone Medical operates in Breath-based diagnostics and biomarker detection.
Key facts
Founded: 2004 · Headquarters: Cambridge, United Kingdom